Erika Hamilton

16.3k citations

432 papers · 8.1k indexed · 8 hit papers · h-index 42

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies

Papers in

Oncology 337
- HER2/EGFR in Cancer Research 173
- Cancer Treatment and Pharmacology 118
- Cancer Immunotherapy and Biomarkers 39
- Lung Cancer Research Studies 31
- PARP inhibition in cancer therapy 30
Pulmonary and Respiratory Medicine 243
- Advanced Breast Cancer Therapies 186

Co-authors: Mythili Shastry Sandra M. Swain Jeffrey R. Infante Sara M. Tolaney Giuseppe Curigliano Manish R. Patel Jorge Chaves Anja von Heydebreck
Journals: Journal of Clinical Oncology (157 papers)Cancer Research (92 papers)Annals of Oncology (41 papers)Gynecologic Oncology (17 papers)Clinical Cancer Research (11 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Erika Hamilton

401 papers receiving 8.0k citations

Hit Papers

8 papers align trajectories log scale

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 2025 · 18 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Journal of Thoracic Oncology
2024 Nature Medicine
2024 Journal of Clinical Oncology
2022 Nature Reviews Drug Discovery
2020 Journal of Clinical Oncology
2019 JAMA Oncology
2017 Breast Cancer Research and Treatment
2016 Cancer Treatment Reviews

Peers

Countries citing papers authored by Erika Hamilton

Since Specialization

Citations

This map shows the geographic impact of Erika Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Hamilton more than expected).

Fields of papers citing papers by Erika Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Hamilton. The network helps show where Erika Hamilton may publish in the future.

Co-authors

The 25 scholars most cited alongside Erika Hamilton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erika Hamilton Line = papers co-authored together Erika Hamilton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer Clinical Cancer Research ·Timothy A. Yap, Jonathan W. Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Yoichi Naito, Antonio Giordano, Igor Bondarenko, Toshinari Yamashita, Li Zhou, Allison Moreau, Heather Neumann, Jessica Tougias, Feng Liu, Jennifer Park, Maria Delioukina, Komal Jhaveri	2025	5
2	Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study. Journal of Clinical Oncology ·Ignacio Melero, Judy S. Wang, Martin Gutierrez, Erika Hamilton, Alexander I. Spira, Drew Rasco, John D. Powderly, Michael Millward, Sophia Frentzas, Rafał Stec, Manish Sharma, Mark Shackleton, Ana Arance, Julia Giner Joaquin, Iwona Ługowska, Tracy Liu, Todd Shearer, Divya Gupta, Jeffrey A. Jones, Víctor Moreno	2024	1
3	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. Journal of Clinical Oncology ·Sònia Pernas, Seock‐Ah Im, Masaya Hattori, Binghe Xu, Shusen Wang, Yen‐Shen Lu, Giuliano Borges, Junji Tsurutani, Komal Jhaveri, Qingyuan Zhang, Michelino De Laurentiis, Noelia Martínez-Jáñez, Erika Hamilton, Hope S. Rugo, Kevin Kalinsky, Sara M. Tolaney, Lei Shi, Sabrina S. Khan, Yanyan Zhu, Aditya Bardia	2024	1
4	Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. Journal of Clinical Oncology ·Manish R. Patel, Rachel M. Layman, Michael Danso, David Cosgrove, Marjorie E. Zettler, Katherine C. Pehlivan, Erika Hamilton	2024	4
5	Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer. Journal of Clinical Oncology ·Fei Ma, Xiaoxiang Guan, Jingfen Wang, Herui Yao, Xian Wang, Erika Hamilton, Yehui Shi, Xinjun Liang, Nong Xu, Huoling Tang, Xiangzhu Tian, Yuhong Zhou, Ziping Wei, Pamela N. Münster	2024	2
6	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial Targeted Oncology ·Erika Hamilton, Gerald S. Falchook, Judy S. Wang, Siqing Fu, Amit M. Oza, Esteban Rodrigo Imedio, Sanjeev Kumar, Lone H. Ottesen, Ganesh Mugundu, Elza C. de Bruin, Mark J. O’Connor, Suzanne F. Jones, David R. Spigel, Bob T. Li	2024	3
7	A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors Clinical Therapeutics ·Gerald S. Falchook, Amita Patnaik, Debra L. Richardson, R. Donald Harvey, Manish Sharma, Navid Hafez, Erika Hamilton, Sarina A. Piha‐Paul, Minal Barve, Trisha M. Wise‐Draper, Manish R. Patel, Afshin Dowlati, Joseph Pascuzzo, Shou‐Ching Tang, Christina Faltermeier, Izabela A. Malinowska, Luda Shtessel, Alina Striha, Elizabeth Potocka	2024	1
8	Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort Cancer Research ·Erika Hamilton, Rinath Jeselsohn, Sara A. Hurvitz, Dejan Juric, Hyo S. Han, Melinda L. Telli, George Zahrah, Rita Nanda, Yuanyuan Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, Cecile Mather, Anne F. Schott	2024	2
9	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. Journal of Clinical Oncology ·Erika Hamilton, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, Joanne Wing-Yan Chiu, José Luiz Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Javier Cortés	2024	5
10	Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292 Cancer Research ·Erika Hamilton, Patrick Neven, Barbara Pistilli, Muralidhar Beeram, Virginia F. Borges, Mario Campone, José Luiz Guimarães, Theodoros Foukakis, Annette Raskov Kodahl, Peter Lau, Elgene Lim, Iwona Ługowska, Greg Rychlik, Christopher Gresty, Claire Miller, Roberto Sommavilla, Dhivya R. Sudhan, Hope S. Rugo	2024	2
11	Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). Journal of Clinical Oncology ·Maxwell R. Lloyd, Azka Ali, Caroline Weipert, Sheila Solomon, Jayati Saha, Marla Lipsyc-Sharf, Erika Hamilton, Kevin Kalinsky, Aditya Bardia, Nicole Zhang, Seth A. Wander	2024	1
12	H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). Journal of Clinical Oncology ·Erika Hamilton, Timothy Pluard, Judy S. Wang, Aki Morikawa, Stephen Johnston, Elizabeth Claire Dees, Christos Vaklavas, Anne Armstrong, Pamela N. Münster, Nisha Unni, Gail Lynn Shaw Wright, Fadi Kayali, Tingting Song, Yuanxin Rong, Kohei Yamaguchi, Dejan Juric	2024	4
13	660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001) Annals of Oncology ·Cesar A. Perez, Jason T. Henry, Nehal J. Lakhani, Justin Call, Erika Hamilton, Gerardo Colón‐Otero, Jennifer R. Diamond, Bert H. O’Neil, A. Kalyan, Guru Sonpavde, Irene Moreno Candilejo, Arif Awan, Elisa Fontana, Pengfei Xu, Fumin Zhang, Natalya Nazarenko, Amita Patnaik	2023	9
14	256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer ESMO Open ·Alexander Philipovskiy, Anne F. Schott, Javier Cortés, Susan E. Ivie, Richard Gedrich, Eric Zhi, J. Ranciato, Jessica M. Perkins, Erika Hamilton	2023	2
15	2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies International Journal of Gynecological Cancer ·Nicole Concin, Manish R. Patel, Vicky Makker, Ana Oaknin, Sandro Pignata, Floor Backes, Antonio González-Martı́n, Ramez N. Eskander, Bhavana Pothuri, Debra L. Richardson, Angeles Alvarez Secord, Els Van Nieuwenhuysen, Joyce F. Liu, Fernanda Musa, Richard T. Penson, Kenton Wride, Rachel L. Dusek, T. Cameron, Erika Hamilton	2022	0
16	33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer Gynecologic Oncology Reports ·Debra J. Richardson, Jill Tseng, Theresa L. Werner, Erika Hamilton, John L. Hays, Linda Duska, Deborah B. Doroshow, Rebecca C. Arend, David Starks, Marilyn Huang, Kyriakos Papadopoulos, Leslie R. DeMars, Emily Putiri, J. D. Barrett, Bhavana Pothuri	2022	2
17	Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity Clinical Cancer Research ·Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Weems, Laura Carter, Xiao Hu, Marshall T. Schreeder, H. Jeffrey Wilkins	2019	47
18	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer Clinical Cancer Research ·Erika Hamilton, Manish R. Patel, Anne Armstrong, Richard D. Baird, Komal Jhaveri, Matthias Hoch, Teresa Klinowska, Justin P.O. Lindemann, Shethah Morgan, Gaia Schiavon, Hazel M. Weir, Seock‐Ah Im	2018	67
19	αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain Clinical Cancer Research ·Dmitry Malin, Elena Strekalova, Vladimír Petrovič, Allison M. Deal, Abraham Al Ahmad, Bárbara Adamo, C. Ryan Miller, Andrey Ugolkov, Chad Livasy, Karen Fritchie, Erika Hamilton, Kimberly Blackwell, Joseph Geradts, Matt Ewend, Lisa A. Carey, Eric V. Shusta, Carey K. Anders, Vincent L. Cryns	2013	81
20	Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing Clinical Cancer Research ·Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith O. Hopkins, Gretchen Kimmick, Justin Favaro, Erika Hamilton, Renee Welch, Sarah Bacus, Kimberly Blackwell	2011	64

About Erika Hamilton

Erika Hamilton is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 432 papers that have together received 8.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (186 papers), HER2/EGFR in Cancer Research (173 papers), Cancer Treatment and Pharmacology (118 papers), Monoclonal and Polyclonal Antibodies Research (58 papers), Ovarian cancer diagnosis and treatment (48 papers), Cancer Immunotherapy and Biomarkers (39 papers), Lung Cancer Research Studies (31 papers) and PARP inhibition in cancer therapy (30 papers). The work is most often cited by research in Oncology (6.0k citations), Pulmonary and Respiratory Medicine (2.8k citations), Cancer Research (1.3k citations), Radiology, Nuclear Medicine and Imaging (1.5k citations) and Reproductive Medicine (510 citations). Erika Hamilton has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Mythili Shastry, Sandra M. Swain, Jeffrey R. Infante, Sara M. Tolaney, Giuseppe Curigliano, Manish R. Patel, Jorge Chaves, Anja von Heydebreck, Fabrice André and H. Grote. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Gynecologic Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact